Drug Profile
Tovetumab
Alternative Names: Anti-PDGFRa MAb - AstraZeneca; MEDI-575Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology
- Developer MedImmune
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Platelet-derived growth factor alpha receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 01 May 2013 MedImmune completes a phase II trial in Glioblastoma (recurrent disease) in USA (NCT01268566)
- 21 Mar 2013 Discontinued - Phase-I for Solid tumours (late-stage disease) in Japan (IV)
- 21 Mar 2013 Discontinued - Phase-I/II for Non-small cell lung cancer (combination therapy, first-line therapy, late-stage disease) in USA, Canada, Hungary and Poland (IV)